GlassScriptPhysician profile
Alessandro Serra
NPI 1730332438
$105,382.22
in general payments reported to CMS, 2019-2025
20 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $18K · 2021: $23K · 2022: $37K · 2023: $542 · 2024: $689 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.35 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $70,823.31 | 2019-2025 | Tysabri, Vumerity, Avonex |
| E.R. Squibb & Sons, L.L.C. | $24,801.62 | 2021-2022 | |
| Celgene Corporation | $7,445.08 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $783.50 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $397.22 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $185.70 | 2019-2025 | Mavenclad |
| Amgen INC. | $148.88 | 2019-2025 | Uplizna |
| Genzyme Corporation | $127.42 | 2019-2025 | |
| Roche Products Limited | $126.25 | 2024 | |
| Horizon Therapeutics Plc | $113.48 | 2022-2023 | Uplizna |
| Abbvie INC. | $105.01 | 2023-2025 | Botox, Ubrelvy |
| Tg Therapeutics, INC. | $97.24 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $73.34 | 2021-2023 | Ponvory |
| Argenx US, INC. | $35.35 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $24.72 | 2025 | Kcentra, Privigen |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.66 | 2019 | |
| Invivyd INC | $20.52 | 2025 | Pemgarda |
| Cycle Pharmaceuticals INC | $20.14 | 2024 | Tascenso Odt |
| Novartis Pharmaceuticals Corporation | $17.53 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alessandro Serra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.